Finance

Lists
Outlook: 61.5% bullish·0.0% bearish
Go to analysis
NOVN:SWX
Novartis AG
CHF 131.50
-0.02%
(-0.020) 1D
Nov 3, 5:30:38 PM GMT+1  ·   CHF
All symbols
SymbolPriceChange% Change
Generating top insights for NOVN...
Open
CHF 133.00
High
CHF 133.12
Low
CHF 131.22
Mkt. cap
265.44B
Avg. vol.
3.32M
Volume
2.85M
Dividend
2.81%
Quarterly dividend
CHF 0.93
Ex-dividend date
Mar 10, 2026
P/E ratio
30.49
52-wk high
CHF 135.06
52-wk low
CHF 99.15
EPS
CHF 4.31
Shares outstanding
2.03B
No. of employees
75K
Open
CHF 133.00
High
CHF 133.12
Low
CHF 131.22
Mkt. cap
265.44B
Avg. vol.
3.32M
Volume
2.85M
Dividend
2.81%
Quarterly dividend
CHF 0.93
Ex-dividend date
Mar 10, 2026
P/E ratio
30.49
52-wk high
CHF 135.06
52-wk low
CHF 99.15
EPS
CHF 4.31
Shares outstanding
2.03B
No. of employees
75K
News stories
From web sources and news partners
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG
CEOVasant Narasimhan
Employees75.3K
FoundedMar 7, 1996
HeadquartersBasel, Basel City, Switzerland
SectorPharmaceutical industry
Websitenovartis.com
Last report
Oct 27, 2026
Fiscal period
Q3 2026
$2.46 / $2.26
+8.63%beat
Revenue / Est. (USD)
15.03B / 14.56B
+3.25%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
13.86B
13.52B
14.95B
15.03B
Cost of goods sold
3.54B
3.44B
3.68B
3.57B
Cost of revenue
3.54B
3.44B
3.68B
3.57B
Research and development expenses
2.84B
2.78B
2.74B
2.98B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.44B
3.14B
3.23B
3.08B
Operating expense
6.46B
5.96B
6.10B
6.31B
Total operating expenses
10.00B
9.40B
9.78B
9.88B
Operating income
3.86B
4.12B
5.18B
5.15B
Other non operating income
-130.00M
4.00M
19.00M
-14.00M
EBT including unusual items
3.22B
3.84B
4.27B
1.32B
EBT excluding unusual items
3.49B
3.78B
4.73B
4.66B
Income tax expense
814.00M
683.00M
1.01B
121.00M
Effective tax rate
25.30%
17.79%
23.71%
9.19%
Other operating expenses
190.00M
42.00M
127.00M
250.00M
Net income
2.41B
3.16B
3.26B
1.20B
Net profit margin
17.38%
23.34%
21.83%
8.00%
Earnings per share
2.03
1.99
2.41
2.46
Interest and investment income
373.00M
-
-
-
Interest expense
-304.00M
-343.00M
-462.00M
-468.00M
Net interest expenses
69.00M
-343.00M
-462.00M
-468.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.96B
5.24B
6.30B
6.38B
Gain or loss from assets sale
80.00M
-159.00M
-247.00M
94.00M
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps